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Abstract
Marginal zone B cells (MZB) mount a rapid antibody response, potently activate naı¨ve T cells, and are enriched in autoreactive
B cells. MZBs express high levels of CD1d, the restriction element for invariant natural killer T cells (iNKT). Here, we examined
the effect of iNKT cells on MZB cell activation and numbers in vitro and in vivo in normal and autoimmune mice. Results show
that iNKT cells activate MZBs, but restrict their numbers in vitro and in vivo in normal BALB/c and C57/BL6 mice. iNKT cells do so
by increasing the activation-induced cell death and curtailing proliferation of MZB cells, whereas they promote the
proliferation of follicular B cells. Sorted iNKT cells can directly execute this function, without help from other immune cells.
Such MZB regulation by iNKTs is mediated, at least in part, via CD1d on B cells in a contact-dependent manner, whereas iNKT-
induced proliferation of follicular B cells occurs in a contact- and CD1d-independent manner. Finally, we show that iNKT cells
reduce ‘autoreactive’ MZB cells in an anti-DNA transgenic model, and limit MZB cell numbers in autoimmune-prone
(NZB6NZW)F1 and non-obese diabetic mice, suggesting a potentially new mechanism whereby iNKT cells might regulate
pathologic autoimmunity. Differential regulation of follicular B cells versus potentially autoreactive MZBs by iNKT cells has
important implications for autoimmune diseases as well as for conditions that require a rapid innate B cell response.
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Introduction
B cells in the spleen anatomically localize in the follicles and
marginal zone and are called follicular B cell (FoB) and marginal
zone B cell (MZB), respectively [1,2]. The MZBs exhibit unique
characteristics not shared by FoBs. Their location in the spleen
helps MZBs mount a rapid antibody response to blood-borne
antigens independently of T cell help [3]. MZBs continuously
shuttle between marginal zone and lymphoid follicles to transport
antigens to follicular dendritic cells [4] and potently activate naı¨ve
CD4+ T cells and quickly differentiate into plasma cells [5]. Rapid
and efficient regulatory mechanism(s) must exist to curb such
prompt and vigorous responsiveness of MZBs to avoid unneces-
sary immune activation.
MZBs are phenotypically distinct from other B cells and are
identified as CD21hi CD35hi CD23low CD9+ IgDlow/2 IgMhi cells
[1,2]. MZBs are also distinct from other B cell subsets through
their high expression of CD1d [6]. Since CD1d presents lipid
antigens to invariant natural killer T (iNKT) cells [7,8,9], MZBs
have been proposed to be important activators of iNKT cells.
However, it is unclear whether iNKT cells, in turn, activate or
regulate MZBs in a way that is different from their interactions
with other B cell populations.
iNKT cells rapidly respond to glycolipid antigens, such as a-
galactosylceramide (aGalCer) [10]. These cells trans-activate a
variety of other cells, including NK cells, conventional T cells, and
B cells [11,12,13,14]. For example, iNKT cells enhance peripheral
blood B cell proliferation [15] and enhance immunoglobulin
production against T-dependent and T-independent antigens and
pathogens [15,16,17,18]. It is unclear whether iNKT cells interact
differently with MZBs that express particularly high levels of
CD1d compared to FoBs.
MZB cells have several features required to break T cell
tolerance. For example, MZB cells can act as robust APCs [5]
and can be easily activated by dendritic cells [19]. In fact, several
studies have linked MZB cell abnormalities to the development of
autoimmune diseases [20,21,22]. MZB cells expand in the non-
obese diabetic (NOD) mouse model of type 1 diabetes (T1D) prior
to the onset of disease at an early age when autoreactive T cells
begin to appear [23,24]. MZB cells are also increased in lupus mice
[25,26], and B cells bearing anti-self B cell receptors
are enriched in the marginal zone of spleens [20,27]. Thus,
understanding mechanisms of MZB cell homeostasis will have
important implications for understanding autoimmune diseases.
In this article, we examined the effects of iNKT cells on the
activation, proliferation and frequency of major B cell subsets in
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the spleen, MZB and FoB, in vitro and in vivo in normal and
autoimmune-prone mice. Our results show that while iNKT cells
activate both MZB and FoB, they selectively curtail the
proliferation of MZBs and promote their activation-induced cell
death (AICD). These results indicate a role of iNKT cells in
regulating the homeostasis of MZBs. Such regulation of MZBs
might be an important mechanism of controlling autoimmune
diseases, since iNKT cells reduce ‘autoreactive’ anti-DNA MZBs
and limit MZBs in lupus-prone NZB/NZW F1 and autoimmune
diabetes-prone NOD mice. These data, along with our recent
report describing the role of iNKT cells in inhibiting autoantibody
production [28], have important implications for the development
of iNKT cell-based therapy in autoimmune diseases.
Materials and Methods
Ethics Statement
All of the scientific data were obtained using high scientific,
technical, and ethical standards. All animal experiments were
approved by UCLA Office of Research Oversight Chancellor’s
Animal Research Committee under protocol ARC # 2005-155.
Mice
BALB/cJ, C57BL/6, NOD/ShiLtJ, NZB and NZW mice were
obtained from the Jackson Laboratory (Bar Harbor, ME) and bred
locally. R4A-c2bTg mice that have increased numbers of IgG2b
anti-dsDNA Ab B cells [20] were provided by Dr. B. Diamond.
Va14Tg [29] and CD1d2/2mice [26] were provided by Dr. A.
Bendelac and Dr. L. VanKaer, respectively. CD1d2/2 BWF1mice
were generated by introgressing CD1d-null allele onto NZB and
NZW backgrounds for 10 and 12 generations, respectively, and
then intercrossing them [30]. The mouse genotype was confirmed
by PCR and their phenotype was confirmed by flow cytometry
using anti-CD1d antibody (1B1) for CD1d2/2 mice and mCD1d/
PBS-57 tetramer for Va14Tg and CD1d2/2 mice [30].
Reagents
The mCD1d/PBS-57 tetramer was obtained from the NIH
Tetramer Core Facility (Emory, GA). Anti-CD93 antibody
(AA4.1) was from eBiosciences; anti-IgM antibody was from
Jackson ImmunoResearch; all other antibodies were from BD
Biosciences (San Diego, CA).
Flow cytometry
Spleen cell suspensions were prepared in staining buffer (0.5%
BSA, 0.09% sodium azide) after red blood cell lysis by Tris-NH4Cl
(pH 7.2). Cells were incubated with anti-CD16/32 (2.4G2) to block
FccRII/III, followed by staining with conjugated mAbs for mouse
antigens, including CD1d (1B1), TCRb (H57-597), CD86 (GL1),
CD69 (H1.2F3), CD95 (Jo2), IgM (mchain specific), CD19 (1D3),
B220 (RA3/6B2), CD21 (7G6), CD23 (B3B4), CD9 (KMC8), active
form of caspase3 (C92-605), 7AAD, and mCD1d/PBS-57 tetramer.
Flow cytometry analysis was performed using FACSCalibur or
FACScan (Becton Dickinson). Data were analyzed using FlowJo
software (Ashland, OR) with lymphocyte gate, based on forward and
side scatter.
Immunohistochemistry
Spleen was embedded in tissue freezing medium (Fisher
Scientific, Pittsburgh, PA) and frozen in liquid nitrogen. Frozen
tissue blocks were sectioned using HM550 cryostat (Mikron, San
Marcos, CA) and 7 mm sections mounted on Superfrost plus slides
(Fisher Scientific). Slides were dried at room temperature (RT),
fixed with cold acetone for 2 min, dried at RT and then rinsed
three times with PBS. Slides were incubated in a humidified
chamber with blocking buffer (20 mg/ml CD16/CD32, 10%
normal mouse serum, 2.5% BSA and 0.1% tween-20 in PBS) for
30 min at RT. Blocked sections were stained with biotin-IgM
(mchain specific, Jackson ImmunoResearch) and FITC-conjugated
MOMA1 (CD169) (AbD Serotec, Raleigh, NC) at 10 mg/ml on
RT for 2 h and then rinsed 5-times with PBST (0.1% Tween20 in
PBS). Slides were further incubated with 2 mg/ml of APC-
conjugated streptavidin (BD Biosciences) for 1 h at RT and then
rinsed 5-times with PBST. Stained slides were mounted with
crystal mount (Biomeda, Foster City, CA) and images captured
using LEICA DM IRB (Meyer instruments, Houston, TX).
Images were analyzed using Leica and Photoshop software.
In vivo immunization
Mice were immunized i.p. with 4 mg of aGalCer or vehicle.
Their spleen was collected at various time points after injection for
analyses.
Purification of T, B and iNKT cells
Spleen cells were incubated with anti-CD90 or anti-CD19
microbeads (Miltenyi Biotec, Auburn, CA) for 20 min at 4uC to
purify T cells and B cells, respectively, using AutoMACS (Miltenyi
Biotec). The purity of T cells and B cells ranged from 82–86%
and 97–98%, respectively. The iNKT cells were sorted as
TCRb+mCD1d/PBS-57 tetramer+ cells and conventional T cells
sorted as TCRb+mCD1d/PBS-57 tetramer2 cells using FACSAria
(Becton Dickinson). The sorted cells were collected in complete
RPMI-1640 medium and checked for their purity (.98%).
Cell culture
Spleen cells at 26106 per ml in complete RPMI-1640 medium
were added to 24-well polystyrene, flat-bottom tissue culture plates
(Corning, Costar, NY) and cultured at 37uC in a humidified 5%
CO2 incubator. Purified B cells (1–2610
6 per ml) were cultured
with or without LPS (10 mg/ml) and aGalCer (50–100 ng/ml).
Sorted T cells or iNKT cells were added to these cultures at 0.5–
16106 cells per ml. Cells were collected at the indicated time points,
stained with indicated antibodies, and analyzed by flow cytometry.
B cell proliferation assay
Purified B cells in complete RPMI-1640 medium were labeled
with carboxyfluorescein diacetate succinimidyl ester (CFSE) with
CellTraceTM CFSE cell proliferation kit (Invitrogen), following
the manufacturer’s instructions. LPS, aGalCer, and sorted T cells
or iNKT cells were added to cultures, as described above. Cells
were collected at the indicated time points, stained with anti-CD19
(PerCP-Cy5.5), anti-CD21 (PE), and anti-CD23 (biotin) antibod-
ies, followed by APC-conjugated streptavidin), and analyzed by
flow cytometry.
Statistical analysis
Descriptive statistics are expressed as the mean 6 SE values.
Comparisons between groups were performed using two-tailed
Student t test or Mann-Whitney U test, and a p value of,0.05 was
considered significant.
Results
iNKT cells activate MZBs, but restrict their numbers in
vivo and in vitro
To determine the effect of iNKT cell activation on different B
cell subsets, we injected aGalCer i.p. in BALB/c mice, including
Innate T Cells Regulate Innate B Cells
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e26536
WT, Va14Tg mice that express the canonical TCR a chain Va14-
Ja18 of iNKT cells [29], and CD1d2/2 mice that have no iNKT
cells [26], and analyzed activation markers on freshly isolated
spleen cells. aGalCer treatment increased CD86 expression on
both MZBs and FoBs from WT or Va14Tg mice, but not from
CD1d2/2 mice (Fig. 1A). Unexpectedly, however, in vivo aGalCer
treatment resulted in a marked reduction in MZB frequency and
marginal zone IgM+ B cells in Va14Tg and WT mice, but not in
CD1d2/2 mice (Fig. 1B–D, and data not shown).
In vitro studies showed that aGalCer was as strong as LPS in
activating MZBs, and acted synergistically with LPS (Fig. 1E).
However, addition of aGalCer to spleen cell cultures reduced the
proportions of MZBs (Fig. 1F, upper panel). Total MZB numbers
were also reduced in the presence of aGalCer (LPS 5.96105;
LPS+aGalCer 0.36105). Similar results were obtained using
spleen cells from Va14Tg mice (data not shown), whereas no
change in MZB cells were seen using spleen cells from CD1d2/2
mice (Fig. 1F, lower panel).
Next, we observed that the reduction of MZB cells in the
presence of aGalCer was not due to its direct binding/effect on
MZB cells (Fig. 2A, left bars), but was mediated by T cells as the
co-culture of B cells with purified T cells from WT mice or
Va14Tg mice [that have ,50% T cells expressing iNKT cell
TCR], but not from CD1d2/2 mice, reduced MZBs (Fig. 2A,
middle and right bars). Strikingly, the presence of sorted iNKT
cells alone was sufficient to reduce MZBs, whereas purified
conventional T cells had no effect on MZB frequency (Fig. 2B,C).
The sorted iNKT cells, in the absence of other T cell subsets, also
markedly enhanced CD23 expression. These data clearly show
that while iNKT cells can activate MZBs and FoBs, they can
directly and selectively restrict the MZB population.
iNKT cells promote AICD of MZBs in vitro and in vivo
Since iNKT cells markedly activate MZBs yet reduce their
numbers, we surmised whether iNKT cells induce AICD of
MZBs. Consistent with this hypothesis, addition of aGalCer to
spleen cells upregulated the expression of apoptotic marker CD95
(Fas) on MZBs in WT or Va14Tg mice, but not in CD1d2/2 mice
(Fig. 3A, and data not shown), while LPS upregulated CD95
expression both in WT as well as in CD1d2/2 mice. CD95
expression on MZBs increased in the presence of purified CD90+
T cells from Va14Tg mice, but not from CD1d2/2 mice in
presence of both LPS and aGalCer (Fig. 3B). Furthermore, sorted
iNKT cells alone could directly increase CD95 expression on
MZBs, without any help from other immune cells (Fig. 3C).
Similar data were obtained, when we examined the effect of
activated iNKT cells on active caspase3, an important mediator of
apoptosis pathway downstream of Fas, by intracellular staining.
Co-culture of B cells in the presence of T cells from Va14Tg mice
or sorted iNKT cells increased caspase3 positive cells among
MZBs, but not among FoBs (Fig. 3D,E). Finally, whereas
activated iNKT cells did not increase apoptotic FoBs, they
increased the proportion of apoptotic MZBs by 6-fold (Fig. 3F).
Similar data were obtained in vivo. After a single aGalCer
injection, CD95 expression on MZBs as well as the frequency of
apoptotic MZBs increased among freshly isolated spleen cells in
WT and Va14Tg mice, but not in CD1d2/2 mice (Fig. 3G,H).
CD95 expression also increased on FoBs in aGalCer-injected WT
and Va14Tg mice, but there was no increase in apoptotic FoBs in
these mice (data not shown). Taken together, these data suggest
that iNKT cells selectively trigger the AICD of MZBs by
enhancing the expression of molecules, CD95 and active caspase3,
in the apoptosis pathway. However, iNKT cells also reduced
MZBs in Fas-mutant MRL-lpr mice (not shown in figure),
suggesting existence of additional mechanism(s) whereby iNKT
cells might regulate MZB cells.
iNKT cells selectively inhibit the proliferation of MZBs,
but not of FoBs
In search for additional mechanisms of iNKT cell-mediated
inhibition of MZBs, we asked if iNKT cells affect the proliferation
of MZBs. CFSE-labeled B cells from WT mice were co-cultured
with T cells from CD1d2/2 or Va14Tg mice. Surprisingly, the
LPS-induced proliferation of MZBs was profoundly inhibited in
cultures containing iNKT cells (Fig. 4A). This inhibitory effect
was directly mediated by iNKT cells, as sorted tetramer+ iNKT
cells, but not tetramer2 conventional T cells, completely
suppressed the proliferation of MZBs (Fig. 4B). In contrast, FoBs
robustly proliferated in the presence of iNKT or conventional T
cells. Thus, iNKT cells have disparate effects on the proliferation
of FoBs versus MZBs.
iNKT cell-mediated inhibition of MZB proliferation is
partly contact- and CD1d-dependent
To investigate mechanisms whereby iNKT cells inhibit MZB
proliferation, we first conducted trans-well culture experiments,
where CFSE-labeled B cells from WT mice were cultured together
or separated in transwells with T cells (Fig. 5A). Results show that
LPS-induced proliferation of MZBs was inhibited by iNKT cells in
both transwells and mixed cultures, suggesting a role of both cell-
cell contact and cytokine-dependent mechanisms in iNKT cell-
mediated inhibition of MZB cells. However, MZB cell prolifer-
ation was more profoundly inhibited in mixed cultures than in
transwells, whereas iNKT cells increased FoB proliferation equally
in transwells and mixed cultures. Thus, the efficient inhibition of
MZB cells by iNKT cells requires contact between these two cell
types.
To investigate mechanisms underlying the contact-dependent
inhibition of MZBs by iNKT cells, we determined the role of
CD1d that is highly expressed on MZB cells. In co-cultures of
Va14Tg T cells with B cells from WT or CD1d2/2 mice, iNKT
cells more profoundly inhibited WT MZBs (Fig. 5A–MZB, mixed
cultures) than CD1d2/2 MZBs (Fig. 5B), whereas iNKT cell-
mediated increase in FoB proliferation was similar in cultures
containing WT B cells (Fig. 5A–FoB) or CD1d2/2 B cells
(Fig. 5B–FoB). Thus, while iNKT cell-induced FoB proliferation
is mediated via soluble factors, iNKT cells inhibited MZBs in a
partly CD1d-restricted, contact-dependent manner.
iNKT cells reduce ‘autoreactive’ MZB cells
The above studies clearly demonstrate the ability of iNKT cells
to restrict MZB population in normal BALB/c mice. Since lupus-
like autoreactive B cells are enriched in MZB population [20,27],
we asked if iNKT cells can inhibit ‘autoreactive’ MZBs. Whole
spleen cells from R4A-c2bTg mice that have increased numbers of
anti-DNA B cells [20] were cultured with LPS in the presence or
absence of aGalCer and MZB cells were enumerated among anti-
DNA B cells (IgG2bhi-gated cells). As shown in Fig. 6A, LPS
markedly expanded the anti-DNA MZB cells, which were reduced
upon addition of aGalCer. Thus, iNKT cells can specifically
regulate autoreactive MZB population.
iNKT cells reduce MZBs in vivo in genetically
autoimmune-prone strains of mice
The above studies showing reduction of anti-DNA MZBs in
presence of iNKT cells prompted us to ask if iNKT cells will
inhibit MZB cells in genetically lupus-prone mice. Results show
Innate T Cells Regulate Innate B Cells
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that addition of aGalCer to spleen cell cultures from diseased 7-
mo-old (Fig. 6B) or preclinical 3-mo-old NZB/NZW F1 mice
(Fig. 6C) selectively reduced the frequency of MZB cells. The
MZB cell changes were not due to direct binding of aGalCer to
CD1d on MZB cells, since adding aGalCer to pure B cells alone
had no effect on MZB cell frequency in lupus mice (Fig. 6C, lower
row). Thus, iNKT cells can regulate MZBs in mice that
spontaneously develop autoimmune disease.
Since MZB cells preferentially secrete IgG3 isotype, we asked if
the presence of iNKT cells would affect the levels of IgG3 isotype.
As shown in Fig. 6D, while serum IgG1 and IgG2a isotype levels
were similar between the two groups, serum IgG3 levels were
higher in CD1d2/2 NZB/NZW F1 mice than in CD1d+/+
littermates. Taken together, these results as well as data in Fig. 1, 4
and 5 provide evidence that iNKT cells can influence various
functions of MZBs including Ig production, activation and
proliferation.
Our results thus far show that iNKT cell effects on MZBs were
particularly pronounced under condition, such as in vitro LPS
exposure, that is known to cause MZB expansion [1]. Conse-
quently, we asked if iNKT cell activation will restrict MZBs in vivo
in animals that spontaneously develop marked MZB expansion.
Results show that NOD mice that have reduced numbers of iNKT
cells [31] exhibit increased MZB cell proportions and numbers
and increased marginal zone B cell area as compared to normal
BALB/c (Fig. 7A) and B6 mice (Fig. 7B), as also reported
previously [23,24]. To further test the role of this association
between reduced iNKT cells and increased MZBs, we treated
NOD mice with aGalCer that expands iNKT cells and prevents
the development of diabetes [32,33]. As shown in Fig. 7B,
aGalCer treatment, as compared to vehicle injection, resulted in a
significant reduction in the frequency of MZBs in NOD mice. B
cells were also reduced in the marginal zones of spleens in
aGalCer-treated NOD mice (Fig. 7C). Thus, iNKT cell
activation can reduce MZB cells in vivo in autoimmune mice that
have expanded MZB population.
Discussion
We report that while iNKT cells activate the two major subsets
of B cells in the spleen, they selectively reduce MZBs in vitro and in
vivo. This reduction in MZBs is at least in part due to their
increased AICD as well as due to reduced proliferation in a partly
CD1d-restricted, contact-dependent manner. In contrast, iNKT
cells promote the proliferation and expansion of FoB cells via
soluble factors. Thus, iNKT cells interact differently with two
major B cell subsets in the spleen, whereby iNKT cells selectively
regulate MZB homeostasis.
We demonstrate the iNKT cell-mediated inhibition of MZBs,
defined as CD121hiCD23lo B cells by flow cytometry, under
various patho-physiological conditions, including normal BALB/c
and B6 mice without or with LPS exposure (Fig. 1B, 7B), anti-
DNATg NZW mice (Fig. 6A), and autoimmune-prone NZB/NZW
F1 and NOD mice that exhibit spontaneous MZB expansion
(Fig. 6B,C, 7B). Similar observations were made using other
markers for MZBs, including CD1dhiCD21hi or CD1dhiCD9+ on
gated CD19+ cells, in B6, NOD (Fig. 7B) and BALB/c mice (data
Figure 1. Effect of aGalCer treatment on activation and numbers of MZBs in vivo and in vitro. A–D. Four-mo-old female CD1d2/2, WT and
Va14Tg BALB/c mice were injected i.p. with 4 mg of aGalCer or vehicle. Their spleens were harvested 3–4 d later and analyzed by flow cytometry and
immunohistochemistry for MZBs. Results using three mice per group from one representative of at least three independent experiments are shown.
A. CD86 expression on gated CD19+CD21hiCD232/low (MZBs) and CD19+CD21+CD23+ (FoBs) in aGalCer (thick line) or vehicle (shaded area) injected
mice. B. MZBs (CD21hiCD232/low) were analyzed on gated CD19+ lymphocytes. MZB frequency is expressed as % of CD19+ lymphocytes in
representative dotplots (B) and as the mean6SE from three each of vehicle or aGalCer-injected WT, CD1d2/2 and Va14Tg mice (C). A significant
reduction of MZBs was found in aGalCer-treated WT (*p,0.05) and Va14Tg mice (**p,0.01), but not in CD1d2/2mice. D. Frozen spleen sections from
aGalCer or vehicle treated mice were stained for APC-IgM (blue) and FITC-MOMA1 (green). Confocal images show IgM+ cells (blue) in the marginal
zone between red pulp and MOMA-1 (green) in CD1d2/2 and vehicle-injected Va14Tg mice. IgM+ cells in the marginal zone are reduced in aGalCer-
treated Va14Tg mice (as indicated by a blue arrow). MZ, marginal zone; RP, red pulp; WP, white pulp. 206and 406magnification. E, F, Spleen cells
(26106 cells per ml) from 3-mo-old BALB/c mice were cultured with or without LPS in the absence or presence of aGalCer (100 ng/ml). Results
represent five independent experiments, each time using cells from one mouse per group. E. Expression of CD69 and CD86 are shown on gated
MZBs (CD19+CD21hiCD232/low) in spleen cells cultured with medium alone (shaded area), aGalCer (blue line), LPS (green line) or LPS+aGalCer (red
line) for 24 h. The MFI of CD69 and CD86 are shown. F. Spleen cells from WT and CD1d2/2 BALB/c mice were cultured without or with LPS and/or
aGalCer for 72 h. MZB cells are expressed as % of mature B cells (AA4.12 IgM+).
doi:10.1371/journal.pone.0026536.g001
Figure 2. iNKT cells can directly inhibit MZBs. A. (left bars)
aGalCer does not directly affect B cells. Purified B cells (1.56106 cells per
ml) from WT BALB/c mice were cultured alone and stimulated with LPS
in the presence or absence of aGalCer for 68 hours. (Middle and right
bars) T cells are sufficient to execute aGalCer-induced regulation of MZB
numbers. Purified B cells from WT BALB/c mice were co-cultured with
purified CD90+ T cells (7.56105 cells per ml) from CD1d2/2 or Va14Tg
mice, with LPS and/or aGalCer. MZBs were analyzed as
IgM+CD21hiCD232/low by flow cytometry and expressed as the mean
6 SE (*p,0.01; n = 3 mice per group) from three independent
experiments. B, C. Sorted iNKT cells reduce MZB cell numbers. Spleen
cells from Va14Tg mice were sorted as iNKT cells (TCRbint mCD1d-PBS57
tetramer+) or conventional T cells (TCRb+ mCD1d-PBS57 tetramer2;
Conv-T). The sorted T cells (56105) were co-cultured with purified B
cells (16106) from WT mice in presence of LPS and aGalCer for 2–3 d.
MZBs were analyzed as CD19+CD21hiCD23low cells, and summarized in
the bar diagram (C) as the mean 6 SE percentage of CD19+ MZBs
(*p,0.01; n = 3 mice per group). Data shown represent three
independent experiments.
doi:10.1371/journal.pone.0026536.g002
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not shown). Further evidence of reduction in MZBs in vivo was seen
by immunohistochemistry showing reduction of B cells in marginal
zones of spleen of BALB/c, B6 and NOD mice treated with
aGalCer.
The MZ subset of B cells exhibits several unique features [34].
In the absence of B cell influx from bone marrow, FoBs in the
spleen gradually decrease in numbers whereas MZBs are
maintained at normal levels [35]. MZBs do not circulate via
blood or lymph, and remain in spleen even after depletion of
recirculating cells [36]. MZBs are more efficient than FoBs to
generate plasma cells after polyclonal in vitro stimulation [37].
Findings in this paper provide evidence for a mechanism whereby
such rapid and potent immune responses elicited by MZBs can be
regulated by iNKT cells that can also respond and act rapidly.
The iNKT cells are a unique T cell subset that responds rapidly
to lipid antigens [8,9,10]. iNKT cells efficiently promote B cell
proliferation and Ig production [15,16,17]. Consistent with these
observations, we found that iNKT cells enhance activation
markers and costimulatory molecules on all B cells (Fig. 1).
However, iNKT cells appear to regulate the two major subsets of
splenic B cells differently. Whereas FoB cells expand and
proliferate in presence of iNKT cells, iNKT cells selectively
restrict the proliferation and numbers of MZBs.
We show evidence for at least two mechanisms, namely AICD
and suppression of proliferation, whereby iNKT cells can control
the homeostasis of MZBs. Cellular and molecular contexts in
which these two cells interact are unclear. It has been proposed
that MZBs that express high levels of CD1d will efficiently activate
iNKT cells [38]. In fact, a recent study showed that MZBs activate
iNKT cells in vivo and in vitro [39]. iNKT cells can in turn
recognize CD1d on MZB cells and activate them. Activated iNKT
cells also express enhanced levels of Fas-L [40], which could
engage Fas on activated MZBs leading to their apoptosis. Such
feedback inhibitory loop may ensure a homeostasis of these two
immune cells after an incidence of rapid cross-activation. In
support of this idea, we show that iNKT cells potently inhibit
MZB cells if they express CD1d. CD1d expression on MZB or
MZB-like cells has also been shown to promote iNKT cell-
dependent tolerance [41] and protection from inflammation [42]
by facilitating iNKT–B cell interactions. Thus, CD1d-restricted
regulation of B cells may be an important mechanism whereby
iNKT cells might discriminate between MZB versus other B cells
leading to their selective regulation versus activation depending on
the context.
iNKT cells can convert tolerogenic B cells into immunogenic
APCs that can induce CD8+ Treg and cytotoxic T cells [43,44],
which can potentially regulate autoreactive B cells [45,46].
However, our data show that iNKT cells can directly confer the
Figure 3. Effect of iNKT cells on apoptosis markers and AICD of MZBs in vitro and in vivo. A–C. iNKT cells increase CD95 expression on
MZBs in vitro. (A) Spleen cells (26106 cells per ml) from CD1d2/2 or Va14Tg BALB/c mice were cultured with medium alone (shaded area), aGalCer
(blue line), LPS (green line) or LPS+aGalCer (red line) for 3 d. Representative histograms show the expression of CD95 on MZBs (CD19+CD21hiCD232/
low). Similar results were obtained when spleen cells from WT mice were used in place of Va14Tg mice. Results are representative of more than five
independent experiments, each time using one mouse per group. (B) B cells purified from WT BALB/c spleen were cultured alone (shaded area) or
with CD90+ T cells from CD1d2/2 mice (green line) or Va14Tg mice (blue line) in the presence of LPS and aGalCer for 2 d. CD95 expression is shown
on gated MZBs from one representative of two experiments, each time using B cells pooled from two mice and T cells pooled from three mice. (C)
Purified CD19+ B cells from WT BALB/c spleen were cultured alone (shaded area) or with sorted iNKT cells (TCRb+tetramer+, blue line) or conventional
T cells (TCRb+tetramer2, green line; Conv-T) from Va14Tg mice for 3 d in the presence of LPS and aGalCer. CD95 expression is shown on gated MZBs
from an experiment using pooled cells from 3–4 mice per group. D, E. iNKT cells increase active caspase3 expression in MZBs. CD19+ B cells (26106
cells per ml) from WT BALB/c mice were cultured with LPS and aGalCer. To these wells, we added CD90+ T cells (16106 cells per ml) from Va14Tg or
CD1d2/2 BALB/c mice (D) or sorted iNKT cells (TCRb+tetramer+) or conventional T cells (Conv-T; TCRb+tetramer2) at 16106 cells per ml (E). After 2–
3 d of cultures, cells were analyzed for the expression of active caspase3 on MZBs and FoBs. Compared to cultures containing CD1d2/2 or tetramer2
T cells, cultures containing Va14Tg T cells or sorted iNKT cells had 3–9-fold higher expression of active caspase3 on MZBs but not on FoBs. Results
represent two independent experiments, each using cells pooled from 2–3 mice per group. F. iNKT cells induce apoptosis of MZBs in vitro. CD19+ B
cells from WT BALB/c mice were cultured with CD90+ T cells from Va14Tg or CD1d2/2 BALB/c mice for 48 h, as in panel D, and expression of 7AAD
was analyzed on FoBs or MZBs. Whereas iNKT cells (T cells from Va14Tg mice) did not increase the proportion of 7AAD+ FoBs, they increased the
proportion of 7AAD+ apoptotic MZBs by 6–7-fold compared to cultures that had no iNKT cells. Results represent two independent experiments, each
using pooled cells from 2–5 mice per group. G. Enhanced CD95 expression on MZBs upon activation of iNKT cells in vivo. 4-mo-old animals were
injected i.p. with 4 mg of aGalCer (thick line) or vehicle (shaded area). Freshly isolated spleen cells were analyzed for CD95 expression on MZBs at 3 d
post-injection. Data represent three independent experiments, each time using one mouse per group. H. Increased apoptosis of MZBs upon
activation of iNKT cells in vivo. Freshly isolated spleen cells from 4–7-mo-old CD1d2/2, WT and Va14Tg mice were analyzed for 7AAD+ apoptotic MZBs.
Data represent three independent experiments, each time using one mouse per group.
doi:10.1371/journal.pone.0026536.g003
Figure 4. Effect of iNKT cells on the proliferation of FoB versus
MZBs. Purified B cells (26106) from WT BALB/c mice were labeled with
CFSE, and cultured alone or co-cultured with CD90+ T cells (16106) from
CD1d2/2 or Va14Tg mice for 5 d (A) or with sorted conventional T cells
(tetramer2; Conv-T) or iNKT (tetramer+) cells (B) for 62–68 h in the
presence of LPS and aGalCer. CFSE level was analyzed on MZBs or FoBs
on gated CD19+ cells. Numbers on the plots represent the % of
proliferating cells. Results are representative of three independent
experiments, each time using spleen cells pooled from 2–3 mice per
group.
doi:10.1371/journal.pone.0026536.g004
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regulatory effects on MZBs by themselves, without help from other
immune cells. A previous study showed that F4/80+ APCs release
a chemokine MIP-2 that recruits iNKT cells to the marginal zones
of spleen where they can aggregate with MZBs and T cells for at
least 7 days [44]. Such close interaction between iNKT cells and
MZBs in splenic marginal zone may result in persistent activation
of MZBs, ultimately leading to their AICD. Fas-mediated
apoptosis is an important negative checkpoint during B cell
development to eliminate autoreactive B cells and control B cell
homeostasis [47]. We propose that Fas-mediated apoptosis
induced by iNKT cells provide an important negative checkpoint
at the level of mature MZBs. Since iNKT cells possess cytotoxic
abilities [48], they may potentially reduce MZBs by killing them.
However, we have so far found no evidence of iNKT cell-
mediated direct killing of MZBs (our unpublished data). Although,
iNKT cell-mediated inhibition of MZB cells was more potent
when the two cells were in contact, some inhibition of MZBs
occurred in a contact-independent manner. Cytokines that
mediate this inhibition remain to be determined. A recent study
has shown that upon stimulation with TLR ligands, peritoneal B1
B cells secrete high levels of IL-10 that then inhibits the
proliferation of the same B1 B cells in an autocrine manner
[49]. Interestingly, we have recently reported that iNKT cells
reduce the numbers of IL-10–secreting B cells [28]. Thus, it would
be interesting to investigate whether iNKT cells directly or
indirectly inhibit IL-10–producing MZB cells [50], whereas IL-4
produced by iNKT cells might promote the activation and
proliferation of FoBs [13]. Alternatively, iNKT cells might affect
factors such as Notch2 or its ligands, BAFF or its receptors,
chemotactic signals such as sphingosine 1 phosphate receptor
(S1pR1), and integrins, which are known to promote the
development, differentiation, migration and splenic retention of
MZBs (reviewed in [51]).
Studies have linked MZB cell abnormalities to the development
of autoimmune diseases [20,21,22,24]. For example, MZB cells
increase in lupus-prone [25,26] and NOD mice prior to the onset
of T1D [23,24]. B cells with anti-self B cell receptors are enriched
in the MZ [20,27]. MZB is also the most potent B cell subset to
activate naı¨ve CD4 T cells [5]. MZB’s ability to present self-
antigens to autoreactive T cells, such as diabetogenic T cells [24],
suggests a role of MZBs in the pathogenesis of autoimmune
diseases. Interestingly, the MZB expansion correlates with the
reduced iNKT cell numbers and functions in NOD mice [31]
(Fig. 7). Impairment in iNKT cells prior to the onset of disease is a
feature of many animal models of autoimmune diseases, including
MRL-lpr and pristane-induced lupus [26,52]. Reduction in NKT
cells also associate with autoimmunity in the relatives of lupus
patients [53]. Furthermore, germline deficiency of iNKT cells is
associated with an expansion of MZB cells in aged mice [54], and
CD1d-deficient BALB/c mice injected with a hydrocarbon oil that
induces lupus-like disease have more MZB cells than CD1d2/2
BALB/c mice injected with PBS [26]. Taken together, it is
reasonable to speculate that iNKT cell impairment might be
related to MZB expansion in autoimmune conditions.
We provide a direct evidence for regulatory interactions
between the two innate immune cells in autoimmunity that iNKT
cell activation reduced MZBs in lupus- and autoimmune diabetes-
prone mice (Fig. 6 and 7), and specifically inhibited ‘autoreactive’
(anti-DNA) MZB cells (Fig. 6A). In fact, iNKT cells can inhibit
autoantibody production, while generally enhancing the normal
antibody response in lupus-prone mice [28]. Similar observations
have been reported in another model where injections of syngeneic
apoptotic cells transiently trigger autoantibody production. In this
model of induced autoantibody production, the absence or
reduction of iNKT cells leads to increased autoreactive B cell
activation without affecting the activation of B cells reactive to
Figure 5. Role of cell–cell contact and CD1d in iNKT cell-mediated inhibition of MZB cells. Purified T cells from CD1d2/2 or Va14Tg BALB/c
mice were co-cultured with CFSE-labeled CD19+ B cells from WT or CD1d2/2 mice in the presence of LPS with or without aGalCer for 4 days. Cells
were then analyzed for CFSE dilution on gated MZBs (TCRb2CD21hiCD232/low) or FoBs (TCRb2CD21+CD23+). Results are representative of two
independent experiments, each time using spleen cells pooled from 2–3 mice per group.
doi:10.1371/journal.pone.0026536.g005
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NP-OVA [55]. Importantly, aGalCer treatment prevents autoim-
mune disease in many experimental models including NOD mice
[32,33]. Such protective effect is believed to be mediated via
promotion of Th2 responses [32,33]. However, protection from
diabetes in NOD mice is still maintained if iNKT cells are unable
to produce or induce IL-4 and other regulatory cytokines
(reviewed in [56]). Although, the role of MZBs in the pathogenesis
of T1D is not proven yet, reduction of autoreactive MZBs in
aGalCer-treated NOD mice should be investigated as an
alternative mechanism whereby aGalCer affords protection in
T1D.
In summary, iNKT cells regulate homeostasis of MZBs that
rapidly respond to blood-borne pathogens and potently activate
autoimmune T cells. We provide evidence for AICD and CD1d-
restricted inhibition of proliferation as two mechanisms whereby
iNKT cells regulate MZB homeostasis. Understanding these
mechanisms will open avenues for manipulation of MZBs in
human autoimmune diseases, since patients with T1D and SLE
and their family members have reduced numbers and/or
responses of iNKT cells [53,56]. The iNKT cell-based manipu-
lation of immune responses is particularly appealing, given the
limited polymorphism in CD1 genes [8], obviating one of the
Figure 6. iNKT cells reduce MZB cells in anti-DNA transgenic and lupus-prone mice. (A). Spleen cells from 4-mo-old R4A anti-DNATg NZW
mice were cultured with LPS without or with aGalCer for 48 h, and analyzed for MZBs as the % of anti-DNA (IgG2bhi) B cells. (B) Spleen cells from 7-
mo-old nephritic BWF1 mice were cultured with aGalCer and/or LPS for 65 h, and analyzed for MZBs as the % of B220+ lymphocytes. (C) Whole
spleen cells or purified splenic B cells from 3-mo-old pre-clinical BWF1 mice were cultured with aGalCer and/or LPS for 18 h, and analyzed for MZBs as
the % of IgM+ lymphocytes. *Note that the addition of aGalCer to spleen cell cultures reduced the proportion of MZB cells. Bar graphs on the right
show results expressed as the mean6SE of three independent experiments performed using pooled cells from 3–4 mice per experiment. #P,0.05
##P,0.01, compared to LPS alone cultures. Results represent three independent experiments. (D). Serum levels of IgG1, IgG2a and IgG3 isotypes are
shown in 8-mo-old CD1d2/2 and CD1d+/+ BWF1 littermates. *p = 0.04, n = 13 CD1d2/2 and 7 CD1d+/+ mice, mean 6 SE.
doi:10.1371/journal.pone.0026536.g006
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Figure 7. aGalCer treatment limits MZB expansion in NOD mice. A. Spleen cells from NOD or normal BALB/c mice were analyzed for MZBs.
Comparison of MZB frequency between NOD and BALB/c mice (n = 6 NOD and 3 BALB/c mice, 8–10-week-old females). Numbers on dot plots
indicate MZBs (CD21hiCD232/low) as the mean6 S.E. % of CD19+ cells (*p,0.001). Bar diagram shows the mean6 S.E. absolute numbers of MZBs per
spleen (*p,0.001). (B, C) Spleens were harvested from 2-mo-old NOD or C57BL/6 mice at 3 d after a single i.p. injection with aGalCer or vehicle (n = 6
mice per group). B, Cells were analyzed for MZBs as CD21hi CD232/low CD1dhi CD9+ cells on gated CD19+ B cells. Numbers on dotplots indicate MZBs
as % of CD19+ B cells. Bar diagrams show the mean6 S.E. % MZBs in NOD mice. Compared to vehicle-injected mice, aGalCer-treated NOD mice had a
significant reduction in MZBs, defined as CD19+CD21hiCD232/low (p = 0.007), CD19+CD21hiCD1dhi (p = 0.0001), CD19+CD1dhiCD9+ (p = 0.009). C,
Frozen spleen sections were stained for APC-IgM (blue) and FITC-MOMA1 (green). Confocal images at 206and 406magnification show the reduced
thickness of marginal zone (MZ) IgM+ cells (blue) in aGalCer-treated mice (as indicated by blue arrows). Data represent three independent
experiments.
doi:10.1371/journal.pone.0026536.g007
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major hurdles of therapies aimed at highly polymorphic MHC
class I and II system. Enhancing this appeal is our finding that
iNKT cells differentially regulate different B cell subsets, thus
allowing a selective manipulation of certain B cell functions.
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